AVXL

Anavex Life Sciences Corp (AVXL) | Rumor.io

Anavex Life Sciences

AVXL

Attention (50-day avg)0%

Attention rank (50-day avg)#708

Bullish sentiment (50-day avg)40%

Price to earnings ratio-4.36

Market capitalization217.8M

Earnings per share-0.14

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-46.4M

Social

What share of all stock conversation is about AVXL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% +0	0% 0	0.02% -0.07

Sep 29

The company's new leadership, led by Terrie and Dr. Missling, is seen as a positive development, with a narrowed pipeline allowing for fiscal responsibility while conducting relationships with regulators.
Anavex Life Sciences is expected to provide updates as they progress, with a potential opportunity for the new team to leverage industry experts and make the company a success.
The company's focus on the Rett and Fragile X trials is seen as a strong area of development, with the potential for quick enrollment and a strong target for the Fragile X trial.

Generated by AI

Sentiment

Of the messages about AVXL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	12.5%	6.58% -7.06	26.86% -21.21	70.51% -6.39
Bearish	87.5%	93.42% +7.06	73.14% +21.21	29.49% +6.39

Bullish· Mar 25

AVXL's recent price drop is a buying opportunity, with the company's FDA prospects and long-term potential making it a hold.
Insider buying and management confidence could help restore confidence in AVXL, with some users suggesting executives should purchase shares to demonstrate their faith in the company.
AVXL's pipeline and intellectual property remain strong, with the potential for FDA approval and a special voucher, as well as future growth in Japan and China, making it a potentially undervalued stock.

Bearish· May 6

The CEO of Anavex Life Sciences Corp. (AVXL) has been terminated for cause, potentially resulting in financial penalties and loss of unvested equity awards.
The termination suggests that the CEO's actions may have caused reputational damage to the company, and that the board may have been aware of misconduct but failed to act earlier.
The CEO's departure may not necessarily improve the company's prospects, as the board's inaction and potential involvement in the CEO's actions may be a cause for concern.

Generated by AI

Topics

Of the messages about AVXL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	61.76%	29.31%
Controversies	—	0%	14.71%	6.19%
Earnings	—	0%	0%	1.13%
Analysts	—	0%	23.53%	28.07%
Technical Analysis	—	0%	0%	12.64%
Macro	—	0%	0%	22.67%

Earnings· Aug 9

Anavex Life Sciences Corp. ($AVXL) reported a loss of $0.06 EPS, beating estimates by $0.04.
The company's quarterly earnings results were announced, with $AVXL beating expectations by $0.04 EPS.
$AVXL's stock gained 26% since its last earnings release, with the company set to report earnings on August 9 after the close.

Announcements· Mar 25

Anavex Life Sciences withdrew its application for European Medicines Agency marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults.
The decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use indicating that it would not be in a position to issue a positive opinion for the application at this time.
Anavex remains committed to the ongoing clinical development of blarcamesine and to advancing potential therapeutic options addressing the significant unmet medical needs of patients living with early Alzheimer's disease.

Controversies· Dec 29

Anavex Life Sciences Corp. ($AVXL) received a subpoena from the SEC on Dec. 22, indicating a formal investigation into unusual market activity surrounding its shares.
The company believes the investigation relates to the recent unusual activity in the market for its shares, and is fully cooperating with the SEC.
The investigation has led to a sharp decline in Anavex's stock price, with some market participants suggesting that the SEC probe is a positive development, as it may help to uncover and address any market manipulation.

Technical Analysis· Dec 6

$AVXL may have a buy signal from Cantor and could rebound to $20-$25, with some analysts and funds potentially accumulating shares.
A Broadening formation on the chart suggests a possible reversal off the bottom, with a liquidity grab expected tomorrow.
$AVXL could bottom at $8.75-$8.85 and reverse, with some traders awaiting a short signal based on 24 signals on the 30-min chart.

Generated by AI

Community

Of the messages about AVXL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.71%	94.61%	92.29%
Newcomers	0%	3.29%	5.39%	7.71%

Regulars· Sep 24

The Anavex Life Sciences Corp. (AVXL) stockholders have voted to elect all six of its director nominees, with the results to be formally published within four business days.
Regulars are pushing for the company to execute its game plan, with some calling for transparency on the plan's details and others expressing skepticism about the company's commitment to shareholders.
The election outcome has been seen as a positive development, with some investors viewing the stock as undervalued given the uncertainty that has been removed by the vote.

Newcomers· Mar 25

Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing-authorization application for blarcamesine in early Alzheimer's disease following negative feedback from the EMA.
The withdrawal of the application has led to a significant decline in AVXL shares, with a 15% drop to $3.58 in premarket trading.
Many newcomers are expressing regret over selling AVXL shares, with one user admitting to being a "smooth brain" and another warning fellow investors to "get out now" due to the company's "ruinous management team".

Generated by AI

-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders –CENTENNIAL, Colo., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. (“PVG”), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex” or the “Company”), announced its plan following its anticipated success in the Company’s upcoming proxy vote. PVG management is optimistic that its slate of highly

11d agosg.finance.yahoo.com

Glass Lewis says Anavex shareholders should vote for PVG Asset nominees

Glass Lewis urges Anavex shareholders to back PVG nominees Hogue and Kolbert, oppose Ma and van der Velden. Read more here.

12d agoSeeking Alpha

Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change

-- Proxy advisor recommends voting “FOR” two of PVG’s director nominees and “AGAINST” two incumbent director nominees including the board’s current chair on the GOLD Universal Proxy Card – -- PVG encourages stockholders to vote to elect all six of its director nominees by voting the GOLD Universal Proxy Card to help the Company realize the full potential of its valuable assets -- CENTENNIAL, Colo., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. (“PVG”), a stockholder of 337,663 sh

13d agoYahoo Finance

PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance

-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board’s nominees – -- It’s too little, too late after a few months of the incumbent board’s half-measures, so stockholders are encouraged to vote the GOLD Universal Proxy Card to elect PVG’s six nominees to help Anavex realize the full potential of its valuable assets while there’s still time -- CENTENNIAL, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PVG Asset Managem

15d agoYahoo Finance

Also Discussed

Investors talking about AVXL also mention

#	Name	Attention
1	Annovis Bio, Inc.ANVS	0%0
2	Cassava Sciences Inc.SAVA	0%new
3	Biogen IncBIIB	0%-0.01
4	BioVie Inc.BIVI	0%0
5	XOMA CorporationXOMA	0%0
6	INmune Bio Inc.INMB	0%0
7	PTC Therapeutics, Inc.PTCT	0%new
8	Can-Fite BioPharma Ltd. ADRCANF	0%0
9	Alector Inc.ALEC	0%new
10	Energy Recovery, Inc.ERII	0%new

Anavex Life Sciences Corp

Healthcare
Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases. The company’s work centers on precision medicine approaches designed to address high unmet medical needs in brain health, with a primary emphasis on advancing candidate medicines through clinical development. Anavex Life Sciences Corp. operates in the biotechnology sector and serves as a research-driven participant in the global pharmaceutical market, where it contributes to the development of potential treatments for complex neurological diseases.

Website

Location

630 5th Avenue

New York, NY, 10111

United States

Social

What share of all stock conversation is about AVXL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% +0	0% 0	0.02% -0.07

Sep 29

The company's new leadership, led by Terrie and Dr. Missling, is seen as a positive development, with a narrowed pipeline allowing for fiscal responsibility while conducting relationships with regulators.
Anavex Life Sciences is expected to provide updates as they progress, with a potential opportunity for the new team to leverage industry experts and make the company a success.
The company's focus on the Rett and Fragile X trials is seen as a strong area of development, with the potential for quick enrollment and a strong target for the Fragile X trial.

Generated by AI

Sentiment

Of the messages about AVXL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	12.5%	6.58% -7.06	26.86% -21.21	70.51% -6.39
Bearish	87.5%	93.42% +7.06	73.14% +21.21	29.49% +6.39

Bullish· Mar 25

AVXL's recent price drop is a buying opportunity, with the company's FDA prospects and long-term potential making it a hold.
Insider buying and management confidence could help restore confidence in AVXL, with some users suggesting executives should purchase shares to demonstrate their faith in the company.
AVXL's pipeline and intellectual property remain strong, with the potential for FDA approval and a special voucher, as well as future growth in Japan and China, making it a potentially undervalued stock.

Bearish· May 6

The CEO of Anavex Life Sciences Corp. (AVXL) has been terminated for cause, potentially resulting in financial penalties and loss of unvested equity awards.
The termination suggests that the CEO's actions may have caused reputational damage to the company, and that the board may have been aware of misconduct but failed to act earlier.
The CEO's departure may not necessarily improve the company's prospects, as the board's inaction and potential involvement in the CEO's actions may be a cause for concern.

Generated by AI

Topics

Of the messages about AVXL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	61.76%	29.31%
Controversies	—	0%	14.71%	6.19%
Earnings	—	0%	0%	1.13%
Analysts	—	0%	23.53%	28.07%
Technical Analysis	—	0%	0%	12.64%
Macro	—	0%	0%	22.67%

Earnings· Aug 9

Anavex Life Sciences Corp. ($AVXL) reported a loss of $0.06 EPS, beating estimates by $0.04.
The company's quarterly earnings results were announced, with $AVXL beating expectations by $0.04 EPS.
$AVXL's stock gained 26% since its last earnings release, with the company set to report earnings on August 9 after the close.

Announcements· Mar 25

Anavex Life Sciences withdrew its application for European Medicines Agency marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults.
The decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use indicating that it would not be in a position to issue a positive opinion for the application at this time.
Anavex remains committed to the ongoing clinical development of blarcamesine and to advancing potential therapeutic options addressing the significant unmet medical needs of patients living with early Alzheimer's disease.

Controversies· Dec 29

Anavex Life Sciences Corp. ($AVXL) received a subpoena from the SEC on Dec. 22, indicating a formal investigation into unusual market activity surrounding its shares.
The company believes the investigation relates to the recent unusual activity in the market for its shares, and is fully cooperating with the SEC.
The investigation has led to a sharp decline in Anavex's stock price, with some market participants suggesting that the SEC probe is a positive development, as it may help to uncover and address any market manipulation.

Technical Analysis· Dec 6

$AVXL may have a buy signal from Cantor and could rebound to $20-$25, with some analysts and funds potentially accumulating shares.
A Broadening formation on the chart suggests a possible reversal off the bottom, with a liquidity grab expected tomorrow.
$AVXL could bottom at $8.75-$8.85 and reverse, with some traders awaiting a short signal based on 24 signals on the 30-min chart.

Generated by AI

Community

Of the messages about AVXL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.71%	94.61%	92.29%
Newcomers	0%	3.29%	5.39%	7.71%

Regulars· Sep 24

The Anavex Life Sciences Corp. (AVXL) stockholders have voted to elect all six of its director nominees, with the results to be formally published within four business days.
Regulars are pushing for the company to execute its game plan, with some calling for transparency on the plan's details and others expressing skepticism about the company's commitment to shareholders.
The election outcome has been seen as a positive development, with some investors viewing the stock as undervalued given the uncertainty that has been removed by the vote.

Newcomers· Mar 25

Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing-authorization application for blarcamesine in early Alzheimer's disease following negative feedback from the EMA.
The withdrawal of the application has led to a significant decline in AVXL shares, with a 15% drop to $3.58 in premarket trading.
Many newcomers are expressing regret over selling AVXL shares, with one user admitting to being a "smooth brain" and another warning fellow investors to "get out now" due to the company's "ruinous management team".

Generated by AI

Anavex Life Sciences

Social

Sep 29

Bullish· Mar 25

Bearish· May 6

Earnings· Aug 9

Announcements· Mar 25

Controversies· Dec 29

Technical Analysis· Dec 6

Regulars· Sep 24

Newcomers· Mar 25

Anavex Life Sciences board election triggers change in control and full vesting of awards

Anavex stockholders elect six directors at annual meeting

PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences

Glass Lewis says Anavex shareholders should vote for PVG Asset nominees

Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change

PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance

Also Discussed

Anavex Life Sciences Corp

Company Information

Location

Anavex Life Sciences board election triggers change in control and full vesting of awards

Anavex stockholders elect six directors at annual meeting

PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences

Glass Lewis says Anavex shareholders should vote for PVG Asset nominees

Glass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change

PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance

Also Discussed

Social

Sep 29

Bullish· Mar 25

Bearish· May 6

Earnings· Aug 9

Announcements· Mar 25

Controversies· Dec 29

Technical Analysis· Dec 6

Regulars· Sep 24

Newcomers· Mar 25